Dasatinib and the Risk of Pulmonary Arterial Hypertension

Published Online: Friday, October 21, 2011
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.

To access the podcast, click here.
Latest Articles
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Anxiety sensitivity has been linked to more debilitating asthma symptoms and greater functional limitations.
Nasal corticosteroid sprays do not seem to be viable treatments for the common cold.
Latest Issues